AML-392 Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123-Targeted Therapy

Pemmaraju, N., Cuglievan, B., Lasky, J., Kheradpour, A., Hijiya, N., Stein, A. S., Meshinchi, S., Mullen, C., Angelucci, E., Vinti, L., Mughal, T. I., & Pawlowska, A. (2022). AML-392 Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123-Targeted Therapy. Clinical Lymphoma Myeloma and Leukemia, 22, S244–S245. https://doi.org/10.1016/s2152-2650(22)01284-8
Authors:
Naveen Pemmaraju
Branko Cuglievan
Joseph Lasky
Albert Kheradpour
Nobuko Hijiya
Anthony S. Stein
Soheil Meshinchi
Craig Mullen
Emanuele Angelucci
Luciana Vinti
Tariq I. Mughal
Anna Pawlowska
Affiliated Authors:
Nobuko Hijiya
Columbia Affiliation:
Author Keywords:
aml
bpdcn
cd123
pediatric
plasmacytoid dendritic cell
tag
tagraxofusp
targeted therapy
elink
Publication Type:
Article
Unique ID:
10.1016/S2152-2650(22)01284-8
DOI:
10.1016/S2152-2650(22)01284-8
Journal:
Clinical Lymphoma, Myeloma and Leukemia
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record

Record Created: